GSK, a global biopharma company developing vaccines and specialty medicines, has hired Tyler Reynolds as Director, Digital Medicine. He joins after three years at AstraZeneca and Evinova, where he worked on digital strategy across oncology and cell therapy. In this role he’ll help shape digital strategy for the company’s respiratory, immunology and inflammation portfolio.
Tyler said, “I’m extremely grateful and appreciative for my time at AstraZeneca & Evinova. Helping to build novel digital strategies and capabilities across oncology and cell therapy was enormously fulfilling and I will miss the deep cross-functional collaboration that made it all possible. I learned a lot from many outstanding colleagues and partners. I look forward to bringing that experience into respiratory, immunology, and inflammation at GSK as my newest challenge.”
About Tyler Reynolds
Reynolds most recently served as Director of Digital Health Strategy for Oncology at AstraZeneca starting in 2023, and he held the same role at Evinova. Evinova is AstraZeneca’s health-tech business focused on digital solutions for clinical research. AstraZeneca launched it in late 2023 as a separate business within the company, offering digital trial solutions, study design and planning, and portfolio management. Before AstraZeneca, Reynolds spent several years at PA Consulting, where he advanced from Analyst to Principal Consultant and focused on life sciences and growth strategy. Earlier in his career, he was an Operations Analyst at The Bryn Mawr Trust Company and an Analyst at Barclays Investment Bank.
Reynolds earned a Bachelor’s degree in Finance from Villanova University.
About GSK
GSK is a global biopharma company that develops vaccines and specialty medicines across infectious diseases, HIV, respiratory and immunology, and oncology. The company is headquartered in London and has major U.S. operations, including sites in Philadelphia and North Carolina’s Research Triangle Park.
